Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human immunodeficiency virus (HIV) antigens are viral proteins that play essential roles in the structure, infectivity, and immune recognition of HIV. These antigens are present on or within the virus particle (virion) and are critical for viral entry into host cells, replication, assembly, and evasion of the host immune response. Key antigens include envelope glycoproteins (gp120, gp41), Gag proteins (p24, p17, p7/p6), and Pol proteins (reverse transcriptase, integrase, protease). These antigens elicit strong humoral and cellular immune responses, but rapid mutation rates lead to antigenic variation that helps HIV evade immunity. Detection of specific HIV antigens, especially p24, is central in early diagnosis.
Various mechanisms depending on the specific antigen, including blocking viral entry, inhibiting reverse transcription, inhibiting protease activity, and inhibiting integration into host DNA.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human Immunodeficiency Virus Antigens (HIV Antigens).